CONCENTRATIONS OF PHOSPHOLIPIDS IN BLOOD SERUM OF GASTRIC CANCER PATIENTS, LEVEL OF TUMOR HYPOXIA: ANALYSIS OF POSSIBLE ASSOCIATION WITH MINIMAL RESIDUAL DISEASE
Keywords:
gastric cancer, hypoxia, disseminated tumor cells, phospholipids, lysophosphatidylcholine.Abstract
Summary. Aim: to determine the possible associations between changes of phospholipids concentrations in blood
serum, levels of primary tumor hypoxia and availability of disseminated tumor cells (DTC) in bone marrow
(BM) in patients with gastric cancer (GC). Patients and
methods: a total of 67 patients with primary GC were diagnosed and treated at the Kyіv City Clinical Oncological Center. The level of tumor hypoxia as well concentrations of phospholipids in blood serum were evaluated
using 31P NMR spectroscopy. DTCs were detected using
immunocytochemistry. Results: it was determined that under low concentrations of lysophosphatidylcholine (LPC
< 0.160 mmol/l) in blood serum in patients the probability of appearance of tumor cells in BM is increased by
a factor of 6,99 (odds ratio 699; 95% confidence interval 1.586–25.508; χ2 = 8.118; p < 0.01) and DTCs in
BM were persisted in 81,8% of patients (p < 0.01) when
primary tumors were characterized by severe and moderate hypoxia. Conclusion: it was shown that there is a relationship between LPC concentrations in blood serum of
GC patients and minimal residual disease, namely: reduction of LPC levels are associated with availability of
DTCs in BM (p < 0.01) and such association is enhanced
by the hypoxia in primary tumor (p < 0.01). It is suggested that changes of LPC concentrations in blood serum of
patients with GC may be as relevant biomarker of tumor
progression for monitoring of disease outcome and may
be of great importance to predict the recurrence especially under individualizing therapy.
References
Kienle P, Koch M. Minimal residual disease in gastrointestinal cancer. Semin Surg Oncol 2001; 20: 282–93.
Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6: 339–51.
Pantel K, Woelfe U. Detection and molecular characterization of disseminated tumor cells: implications for anti-cancer therapy. Biochim Biophys Acta 2005; 1756: 53–64.
Jauch K-W, Heiss MM, Gruetzner U, et al. Prognostic significance of bone marrow micrometastases in patients with gastric
cancer. J Clin Oncol 1996; 14: 1810–17.
Osinsky S, Vaupel P. Tumor microphysiology. Kiev: Naucova Dumka, 2009: 94–108.
Semenza GL. Cancer-stromal cell interactions mediated by
hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 2013; 31 (35): 4057–63.
Walsh JC, Lebedev A, Aten E, et al. The clinical importance
of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxidants Redox Signaling 2014; 21: 1516–54.
Chouaib S, Messa Y, Couve S, et al. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Frontiers
in Oncol 2012; 3: article 21, 1–10.
Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected
physiological pathways. Cancer Metabolism 2014; 2: 3–7.
Bubnovskaya L, Kovelskaya A, Gumenyuk L, et al. Disseminated tumor cells in bone marrow of gastric cancer patients: correlation with tumor hypoxia and clinical relevance. J Oncol 2014;
, Article ID 582140, 7 p.
Podo F. Tumor phospholipid metabolism. NMR Biomed
; 12: 413–39.
Tuz MA, Kuliszkiewicz-Janus М, Baczyński S. Application
of 31Р magnetic resonаnce spectroscopy to observation of phospholipid concentration changes in blood serum, plasma, peripheral blood mononuclear cells and bone marrow mononuclear cells
from patients with hematological cancer — a methodological review. Polish J Chem 2006; 80: 1009–19.
Evelhoch J, Garwood M, Vigneron D, et al. Expanding the
use of magnetic resonance in the assessment of tumor response to
therapy: workshop report. Cancer Res 2005; 65: 7041–5.
Rafflet K, Moka D, Süllentrop F, et al. Systemic alterations in phospholipid concentrations of blood plasma in patients
with thyroid carcinoma: an in vitro 31P high-resolution NMR study.
NMR Biomed 2000; 13: 8–13.
Süllentrop F, Moka D, Neubauer S, et al. 31P NMR spectroscopy ob blood plasma: determination and quantification of
phospholipid classes in patients with renal cell carcinoma. NMR
Biomed 2002; 15: 60–8.
Merchant TE, Rasiumos JN, de Graaf PW, et al. Pospholipid profiles of human colon cancer using 31P magnetic resonance
spectroscopy. Int J Colorectal Dis 1991; 6: 121–26.
Merchant TE, Meneses P, Gierke LW, et al. 31P magnetic
resonance phospholipidprofiles of neoplastic human breast tissue.
Br J Cancer 1991; 63: 693–98.
Kuliszkiewicz-Janus M, Janus W, Baczyński S. Application
of 31P NMR spectroscopy in clinical analysis of changes of serum
phospholipid in leukemia, lymphoma and some other non-hematological cancers. Anticancer Res 1996; 16: 1587–94.
Kuliszkiewicz-Janus M, Tuz MA, Kielbiński M, et al. 31P
MRS analysis of the phospholipid composition of the peripheral
blood mononuclear cells (PBMC) and bone marrow mononuclear cells (BMMC) of patients with acute leukemia (ASL). Cell Mol
Biol Lett 2009; 14: 35–45.
Evelhoch J, Garwood M, Vigneron D, et al. Expanding the
use of magnetic resonance in the assessment of tumor response to
therapy: Workshop Report. Cancer Res 2005; 65: 7041–4.
Бубновська ЛМ, Михайленко ВМ, Ковельська АВ
та ін. Визначення концентрації фосфоліпідів в сироватці
крові хворих на рак шлунка за допомогою 31P ЯМР спектроскопії. Зб: Лучевая диагностика, лучевая терапия 2014;
–4: 20–7.
International Union Against Cancer, TNM Classification
of Malignant Tumors, ed. by L.H. Sobin and C. Wittekind, Wiley-Liss, New York, NY, USA, 6th edition, 2002.
Fenoglio-Preiser C, Carneiro F, Correa P, et al. Gastric
carcinoma. In: World Health Organization Classification of Tumors. Tumours of the Stomach (SR Hamilton LA Aaltonen, eds.),
Lyon, IARC Press 2000; 3: 39–52.
Бубновська ЛМ, Ковельська АВ, Болдескул ІЄ та ін. Рівень гіпоксії у тканині раку шлунка та перебіг захворювання.
Онкологія 2009; 1: 39–43.
Vaupel P, Okunieff P, Kallinowski F, et al. Correlation between 31P-NMR spectroscopy and tissue O2 tension measurements
in a murine fibrocarcoma. Radiat Res 1989; 120: 477–93.
Rofstad EK, De Muth D, Fenton BM, Sutherland RM. 31Р
Nuclear magnetic resonance spectroscopy studies of tumor energy metabolism and its relationship to intracapillary oxyhemoglobin saturation status and tumor hypoxia. Cancer Res 1988; 48:
–46.
Osinsky S, Bubnovskaya L, Ganusevich I, et al. Hypoxia,
tumour-associated macrophages, microvessel density, VEGF and
matrix metalloproteinases in human gastric cancer: interaction and
impact on survival. Clin Transl Oncol 2011; 13: 133–38.
Glickson JD, Evanochko WT, Sakai TT, Ng NC. In vivo
NMR studies of RIF-1 tumors. In: Magnetic Pesonance in Cancer. Allen P, Boisvert DPJ, Lenth BC (eds), Toronto: Pergamon
Press, 1986: 71–82.
Vaupel P, Maye A. Hypoxia in cancer: significance and
impact on clinical outcome. Cancer Met Rev 2007; 26: 225–39.
Alix-Panabières C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res
; 14: 5013–21.
Lin H, Balic M, Zhengу S, еt al. Disseminatedand circulating tumor cells: role in effective cancer management. Crit Rev
Oncol/Hematol 2011; 77: 1–11.
Sasagawa T, Okita M, Murakami J, et al. Abnormal serum lisophospholipids in multiple myeloma parients. Lipids 1999;
: 17–21.
Shida D, Kitayama J, Yamaguchi H, et al. Lysophosphatidic Acid (LPA) enhanced the metastatic potential of human
colon carcinoma DLD1 cells through LPA1. Cancer Res 2003;
: 1706–11.
Oda SK, Strauch P, Fujiwara Y, et al. Lysophosphatidic
Acid inhibits CD T-cell activation and control of tumor progression. Cancer Imminol Res 2013; 1: 245–55.
Mclntyre TM, Pontsler A, Silva A, et al. Identification of
an intracellular receptor for Lysophosphatidic Acid (LPA): LPA is
a transcellular PPARγ agonist. PNAS 2003; 100: 131–36.
